Modified Beta Thymosin Peptides

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes compositions and methods for producing modified beta thymosin peptides where the methionine amino acid is either oxidized, replaced by a different non-methionine amino acid, or both. These modifications increase peptide stability by preventing oxidation, while retaining or altering biological activity, such as actin binding and anti-inflammatory properties. The patent also covers the separation and use of specific enantiomers (R- and S- forms) of oxidized peptides, which can have distinct biological effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Development of more stable therapeutic peptides for use in wound healing and tissue repair.
• Formulation of anti-inflammatory drugs with enhanced pharmaceutical stability.
• Creation of specialized cosmetics for skin regeneration and anti-aging.
• Production of peptides for research applications needing high oxidative stability.
• Designing new peptide drugs for cardiovascular or immune system disorders.
• Targeted drug delivery where peptide degradation is a concern.

BenefitsContent extracted from patent full text and abstract with AI.

• Improved stability of beta thymosin peptides due to resistance to oxidation or degradation.
• Maintained or enhanced biological activity, such as actin binding, despite amino acid substitution.
• Potential for new or unique biological properties owing to unpredictable effects from modifications.
• Access to pure enantiomers, enabling selective therapeutic applications and reduced side effects.
• Broader applicability across pharmaceuticals, cosmetics, and research tools due to robust peptide profiles.
• Opportunity to treat or prevent diseases and injuries with more reliable and effective peptide compositions.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A composition including an oxidized or superoxidized methionine-containing beta thymosin peptide, isoform thereof, fragment thereof, isolated R-enantiomer thereof or isolated S-enantiomer thereof, other than racemic thymosin beta 4 sulfoxide, or a modified beta thymosin peptide, isoform or fragment thereof with an amino acid substituent substituted for at least one methionine of an amino acid sequence of a normally methionine-containing beta thymosin peptide, isoform or fragment thereof, and method for forming same.